Navigation Links
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Date:11/26/2007

Following FDA Approval, Agreement will Broaden Access to

Cholesterol-Reducing Medicine

PHILADELPHIA and WHITEHOUSE STATION, N.J., Nov. 26 /PRNewswire/ -- GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR(R) (lovastatin). Under the agreement, GSK will have exclusive rights to market non-prescription MEVACOR in the United States. Terms of the agreement are confidential but include milestone and royalty payments from GSK to Merck.

MEVACOR was introduced in the United States in 1987 by Merck as the first in a class of cholesterol-reducing medicines known as "statins". The U.S. patent for MEVACOR expired in 2001.

Commenting on the agreement, JP Garnier, chief executive officer, GlaxoSmithKline said, "This new partnership with Merck will enable GSK to address the important public health issue of high cholesterol and help patients better manage their health. OTC Mevacor will be a dynamic new addition to our fast-growing over-the-counter business and is further evidence of GSK's ability to partner in new OTC switch opportunities."

"With MEVACOR, Merck pioneered the development of cholesterol-lowering medicines known as "statins" which are recognized worldwide and remain the standard of care today," said Richard T. Clark, chief executive officer, Merck. "We are pleased to be able to partner with GSK as a way to bring MEVACOR directly to consumers in the United States."

Application for OTC MEVACOR to be reviewed by FDA

The new drug application (NDA) for OTC MEVACOR will be reviewed by the U.S. Food and Drug Administration (FDA) in a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) on December 13. The NDA, filed by Merck, is seeking approval of
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... KY (PRWEB) September 30, 2014 Up ... people in the United States alone have sleep apnea. ... and of those treated, many cannot tolerate their prescribed ... supplied through a nasal mask) – which supports the ... night’s sleep has become especially valuable, and increasingly difficult ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
(Date:9/30/2014)... Youth Town’s annual BBQ/Music Festival will take ... p.m. at the Youth Town campus (3641 Youth Town ... family-oriented festival, which will offer music, food and games. ... car show, arts and crafts fair, music, championship barbeque ... Lightning McQueen and Mater from the hit Disney movie ...
(Date:9/30/2014)... September 30, 2014 Top10inaction.com, one of ... on ranking and reviewing all essential categories in daily ... announced the best liquid foundation at http://top10inaction.com/liquid-foundations/ , ... is named as the best foundation of them all. ... well as high end brands, hence customers have more ...
(Date:9/30/2014)... September 30, 2014 3M has added four ... high bond tapes. 3M 5906 , 3M 5907 ... are conformable VHBs which help create the strongest bond possible ... are used for bonding to difficult surfaces such as paints, ... 5906, 5907, 5908, and 5905 are designed specifically for electronic ...
Breaking Medicine News(10 mins):Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2Health News:Yves Saint Laurent is Named As Best Liquid Foundation 2014 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3
... The University of Pittsburgh Cancer Institute (UPCI) today ... F. Shapira BRCA Cancer Research Program. BRCA 1 and ... the risk of breast, prostate, ovarian and pancreatic cancers. ... this research program to UPCI, said Ronald Herberman, M.D., ...
... people on trial were granted the right to an interpreter ... by UCL (University College London) scientists. The use of family ... teachers and eventually written testimony, which may have disadvantaged the ... British Sign Language was emerging. , The study, ...
... debt and expands available credit facility, HATBORO, ... leading technology provider of enterprise mobility solutions for,the ... has,completed a senior debt financing of up to ... HTGC )., (Logo: http://www.newscom.com/cgi-bin/prnh/20071101/NETH165LOGO ...
... country and online offer opportunity to save a life, ... of adding,46,000 new members to the marrow Registry during ... Marrow Donor Program,s largest,annual awareness campaign, kicks off today., ... other,life-threatening diseases, a marrow transplant offers a second chance ...
... and atypical cells also indicate high risk of second cancer, study ... have been diagnosed with breast cancer, having a known mutation in ... second cancer, and many of these women choose to have their ... However, new research suggests that women who don,t have ...
... May 5 Facet Solutions, Inc., a privately,held ... announced the successful completion of a scientific,evaluation for ... The study,evaluated the combination of Facet Solutions, Anatomic ... device in a,finite element model. The details of ...
Cached Medicine News:Health News:Research program focuses on genetic mutations and cancer risk 2Health News:'Deaf by God' tried in Old Bailey records 2Health News:'Deaf by God' tried in Old Bailey records 3Health News:InfoLogix Completes $25 Million Senior Debt Financing 2Health News:InfoLogix Completes $25 Million Senior Debt Financing 3Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 2Health News:National Marrow Donor Program(R) Kicks off National Awareness Campaign 3Health News:BRCA Mutations Don't Spot All High-Risk Women 2Health News:BRCA Mutations Don't Spot All High-Risk Women 3Health News:Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study 2
(Date:9/29/2014)... SAN DIEGO , 29. ... Ltd. (nachstehend Daiichi Sankyo) (TSE: 4568) und ... gaben heute gemeinsam eine definitive Fusionsvereinbarung bekannt, ... von Ambit Biosciences für 15 US-Dollar je ... anschließenden Zusammenschluss mit einem Tochterunternehmen von Daiichi ...
(Date:9/29/2014)... IRVING, Texas , Sept. 29, 2014 /PRNewswire/ ... 340B Drug Pricing Program, has announced that it ... Services Administration (HRSA) to continue serving in its ... 2019. Apexus, which has held this position for ... with more than 25,000 safety-net provider locations, drug ...
(Date:9/29/2014)... SEATTLE , Sept. 29, 2014 ... leverages Next Generation Sequencing to profile the adaptive ... a Scientific Advisory Board to provide strategic and ... diagnostic suite of assays in the diagnosis and ... initial focus of the SAB will be to ...
Breaking Medicine Technology:Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Apexus Wins HRSA Contract to Remain Prime Vendor of 340B Program 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
... Medical Inc. (TMI),announced today that it has been ... commercialize in Europe the Antares(TM) Coronary,Stent System, a ... use,at or near coronary bifurcations., Representing the ... potential use in a quarter of the 2.2 ...
... Line Clinical Results Expected in November 2008, BOTHELL, ... ) announced today the completion of patient enrollment and ... evaluate the safety and,efficacy of its formulation of 12-hour ... expects to report top-line,results from this pivotal trial in ...
Cached Medicine Technology:TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3
... The PRO6000 power supply ... Thermo's power supply product offering. ... proteomic and genomic electrophoresis. This ... to proteomic applications such as ...
... voltage power supply, the 105 is very simple ... switch control the output, which is variable in ... two-position switch toggles the bright LED display from ... is equipped with an over current detector for ...
... supply is capable of producing up to 250 ... operates in constant voltage or constant current with ... over from one mode of operation to the ... A dual function, auto ranging 24-hour up/down ...
... is designed for horizontal and vertical gel ... be accomplished. In this power supply model, ... current or constant voltage. Four sets of ... connected simultaneously. This power supply's light, compact ...
Medicine Products: